Kala Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Corporate Update

WATERTOWN, Mass.--(BUSINESS WIRE)--Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today reported financial results for the second quarter ended June 30, 2020. “We are very pleased with our progress in the second quarter,” said Mark Iwicki, Chairman, President and Chief Executive Officer of Kala Pharmaceuticals. “In May, the FDA accepted our NDA resubmission for EYS

Full Story →